Prosecution Insights
Last updated: May 29, 2026

Examiner: LUSI, ELLIS FOLLETT

Tech Center 1600 • Art Units: 1677

This examiner grants 66% of resolved cases

Performance Statistics

65.6%
Allow Rate
+5.6% vs TC avg
100
Total Applications
+52.7%
Interview Lift
1420
Avg Prosecution Days
Based on 64 resolved cases, 2023–2026

Rejection Statute Breakdown

3.5%
§101 Eligibility
5.9%
§102 Novelty
59.5%
§103 Obviousness
7.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18252605 DEVELOPMENT OF A NOVEL ELISA-BASED POINT-OF-CARE ANTIGEN TEST FOR SARS-COV-2 Non-Final OA The Regents of the University of California
18029606 HIGH-THROUGHPUT METHOD FOR LP(A)-CHOLESTEROL QUANTITATION Final Rejection The Regents of the University of California
18173002 ASSAYS AND REAGENTS FOR CHARACTERIZATION OF MHCI PEPTIDE BINDING Non-Final OA GENENTECH, INC.
17782742 COMPANION DIAGNOSTICS FOR COMPLEMENT INHIBITORS Final Rejection THE JOHNS HOPKINS UNIVERSITY
17025664 HANDHELD SENSOR FOR RAPID, SENSITIVE DETECTION AND QUANTIFICATION OF SARS-CoV-2 FROM SALIVA Final Rejection University of Florida Research Foundation, Inc.
18032817 METHOD FOR EVALUATING THE MECHANOBIOLOGICAL PROPERTIES OF A CELL ELEMENT Non-Final OA UNIVERSITÉ PARIS CITÉ
18247945 GDF3 AS BIOMARKER AND BIOTARGET IN POST-ISCHEMIC CARDIAC REMODELING Non-Final OA UNIVERSITÉ PARIS CITÉ
17279025 HIGH THROUGHPUT EPITOPE IDENTIFICATION AND T CELL RECEPTOR SPECIFICITY DETERMINATION USING LOADABLE DETECTION MOLECULES Non-Final OA 10x Genomics, Inc.
17650730 LATERAL FLOW ASSAY WITH SAMPLE ADEQUACY LINE Final Rejection Becton, Dickinson and Company
16932533 MULTIPLEX LATERAL FLOW ASSAY FOR DIFFERENTIATING BACTERIAL INFECTIONS FROM VIRAL INFECTIONS Final Rejection Becton, Dickinson and Company
16890372 LATERAL FLOW ASSAY AND METHODS FOR DETECTING HIGH CONCENTRATION ANALYTES Final Rejection Becton, Dickinson and Company
18061672 PLASMON-ENHANCED FLUORO-DOT ASSAYS Non-Final OA Washington University
17426563 IMMUNOCHROMATOGRAPHIC TEST KIT FOR EXTRACTING AND MEASURING SUGAR CHAIN ANTIGENS, CAPABLE OF CONTROLLING ANALYTE DEVELOPMENT Final Rejection Denka Company Limited
18042730 COMPOSITIONS AND METHODS FOR EARLY DETECTION OF OSTEOPOROSIS Non-Final OA New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special
17263667 METHODS FOR DEPLETION AND ENRICHMENT Non-Final OA Veravas, Inc.
17794750 DETECTING GUT BARRIER DYSFUNCTION AND/OR CIRRHOSIS Final Rejection MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED
17771633 METHOD FOR DIAGNOSING FIBRINOLYTIC INSUFFICIENCY RELATED TO NEUTROPHIL EXTRACELLULAR TRAPS Non-Final OA lNSERM-lnstitut National de la Santé et de la Recherche Médicale
17599475 ARTERIOSCLEROSIS AND ARTERIOSCLEROSIS-RELATED DISEASE MARKER Non-Final OA National Cerebral and Cardiovascular Center
17598612 IMMUNOASSAY DEVICE AND IMMUNOASSAY METHOD Non-Final OA INVITROS CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month